News & Updates

The use of transdermal oestradiol (tE2) or oestrogen patches helps suppress testosterone and prostate-specific antigen (PSA) in men with locally advanced prostate cancer, with similar efficacy to that of luteinizing hormone-releasing hormone (LHRH) analogues, reports a study presented at EAU 2025.

Long-term prostate cancer survivors report high levels of self-efficacy, but the contrary is true for subgroups who are facing some challenges, a study presented at EAU 2025 has found.

A comprehensive analysis of circulating proteins identifies known and novel proteins associated with the progression of diabetic kidney disease (DKD) in Asians with younger-onset type 2 diabetes (YT2D; T2D onset age <40 years).

Augmenting comprehensive clinical assessment (CCA) with invasive urodynamic investigations does not appear to benefit women with refractory overactive bladder (OAB) symptoms in the FUTURE* study presented at EAU25.

The combination regimen of clomipramine and sildenafil led to better outcomes than clomipramine or sildenafil alone in men with premature ejaculation (PE) without erectile dysfunction (ED), according to a study presented at EAU25.

Anaemia affects 52.4 percent, while iron deficiency is present in 20.7 percent of Hong Kong patients with advanced prostate cancer (CaP), according to findings from a local cohort.

Testosterone recovery to a normal level appears predictive of improved overall survival (OS) among men with intermediate-risk prostate cancer who underwent androgen-deprivation therapy (ADT) and radiation therapy (RT), suggests a study.

Initial results of the phase I RUTIVAC-1 study show the potential of two doses of a tuberculosis (TB) vaccine given after surgery but before standard BCG* treatment to boost immunity and reduce the odds of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).